These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38648648)

  • 1. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.
    Keating PE; Hock BD; Chin PKL; O'Donnell JL; Barclay ML
    Ther Drug Monit; 2024 Oct; 46(5):619-626. PubMed ID: 38648648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
    Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
    Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
    Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
    Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
    Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation.
    Karsten C; Grannas K; Bergman O; Movérare R; Roforth M; Willrich MAV; Snyder MR; Yang YK
    AAPS J; 2024 Jul; 26(5):86. PubMed ID: 39044059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
    Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
    Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
    Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.
    Clarke WT; Papamichael K; Vande Casteele N; Germansky KA; Feuerstein JD; Melmed GY; Siegel CA; Irving PM; Cheifetz AS
    Inflamm Bowel Dis; 2019 Oct; 25(11):e143-e145. PubMed ID: 31559417
    [No Abstract]   [Full Text] [Related]  

  • 12. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab.
    Suzuki T; Tada M; Ishii-Watabe A
    Biologicals; 2020 Jan; 63():39-47. PubMed ID: 31883741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.
    Rubin DT; Naik S; Kondragunta V; Rao T; Jain A
    Curr Med Res Opin; 2017 May; 33(5):837-843. PubMed ID: 28145781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
    Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum.
    Hock BD; Smith SM; McEntyre CJ; McKenzie JL; Sies C; Keating PE
    J Immunol Methods; 2019 Nov; 474():112672. PubMed ID: 31525368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
    Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
    Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.
    Vroemen WHM; Agata SS; van Beers JJBC; Damoiseaux JGMC
    Antibodies (Basel); 2024 Sep; 13(3):. PubMed ID: 39311378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.
    Keating PE; Hock BD; Smith SM; Chin PKL; O'Donnell JL; Barclay ML
    Intern Med J; 2023 Nov; 53(11):2123-2127. PubMed ID: 37997271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.